Accuracy of fecal occult blood screening for colorectal neoplasia: A prospective study using Hemoccult and HemoQuant tests

David A. Ahlquist, Harry S. Wieand, Charles G. Moertel, Douglas B. McGill, Charles Lawrence Loprinzi, Michael J. O'Connell, James A. Mailliard, James B. Gerstner, Kishan Pandya, Ralph D. Ellefson

Research output: Contribution to journalArticle

289 Citations (Scopus)

Abstract

Objectives. - To define the validity of fecal blood as a marker for colorectal neoplasia in the screening setting and to compare yields by Hemoccult and HemoQuant fecal occult blood screening tests. Design. - A multicenter masked comparison of fecal blood test results against structural colorectal evaluations and longitudinal follow-up, serving as criterion standards, in nonreferred subjects at risk for colorectal neoplasia. Setting. - Communities, primary care centers, referral centers. Participants. - Two groups: (1) 1217 patients aged at least 18 years undergoing routine structural surveillance evaluations following curative resection of a colorectal tumor and (2) 12 312 relatives of colorectal cancer patients aged at least 50 years. Interventions. - Blinded Hemoccult II and HemoQuant testing on three mailedin stool samples per subject. Main Outcome Measure. - Sensitivity of fecal blood tests for colorectal neoplasia. Results. - In the postresection group, surveillance evaluations revealed 46 malignant colorectal neoplasms and 402 polyps. At matched specificity, sensitivity of either test for cancer was 26% (95% confidence interval, 13% to 39%). Hemoccult was positive in 21% of intraluminal recurrences, 33% of all new primary tumors, and 29% of Dukes A or B cancers; HemoQuant was elevated in 24%, 28%, and 29%, respectively. Sensitivity for polyps 1.0 cm or larger was 13% by Hemoccult and 11% by HemoQuant. In the group of relatives, estimated sensitivity for cancer at 1 to 3 years of follow-up was 25% to 33% by Hemoccult, not significantly different from the 29% to 43% by HemoQuant. Conclusions. - Based on our observations in the screening setting, fecal blood appears to be a poor marker for colorectal neoplasia. Most cancers and the vast majority of polyps will be missed. Hemoccult and HemoQuant are similarly insensitive.

Original languageEnglish (US)
Pages (from-to)1262-1267
Number of pages6
JournalJournal of the American Medical Association
Volume269
Issue number10
StatePublished - Mar 10 1993

Fingerprint

Occult Blood
Prospective Studies
Neoplasms
Hematologic Tests
Polyps
Colorectal Neoplasms
Primary Health Care
Referral and Consultation
Outcome Assessment (Health Care)
Confidence Intervals
Recurrence
Sensitivity and Specificity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ahlquist, D. A., Wieand, H. S., Moertel, C. G., McGill, D. B., Loprinzi, C. L., O'Connell, M. J., ... Ellefson, R. D. (1993). Accuracy of fecal occult blood screening for colorectal neoplasia: A prospective study using Hemoccult and HemoQuant tests. Journal of the American Medical Association, 269(10), 1262-1267.

Accuracy of fecal occult blood screening for colorectal neoplasia : A prospective study using Hemoccult and HemoQuant tests. / Ahlquist, David A.; Wieand, Harry S.; Moertel, Charles G.; McGill, Douglas B.; Loprinzi, Charles Lawrence; O'Connell, Michael J.; Mailliard, James A.; Gerstner, James B.; Pandya, Kishan; Ellefson, Ralph D.

In: Journal of the American Medical Association, Vol. 269, No. 10, 10.03.1993, p. 1262-1267.

Research output: Contribution to journalArticle

Ahlquist, DA, Wieand, HS, Moertel, CG, McGill, DB, Loprinzi, CL, O'Connell, MJ, Mailliard, JA, Gerstner, JB, Pandya, K & Ellefson, RD 1993, 'Accuracy of fecal occult blood screening for colorectal neoplasia: A prospective study using Hemoccult and HemoQuant tests', Journal of the American Medical Association, vol. 269, no. 10, pp. 1262-1267.
Ahlquist, David A. ; Wieand, Harry S. ; Moertel, Charles G. ; McGill, Douglas B. ; Loprinzi, Charles Lawrence ; O'Connell, Michael J. ; Mailliard, James A. ; Gerstner, James B. ; Pandya, Kishan ; Ellefson, Ralph D. / Accuracy of fecal occult blood screening for colorectal neoplasia : A prospective study using Hemoccult and HemoQuant tests. In: Journal of the American Medical Association. 1993 ; Vol. 269, No. 10. pp. 1262-1267.
@article{14e2c897e44c4590879cbe8e64b7afb9,
title = "Accuracy of fecal occult blood screening for colorectal neoplasia: A prospective study using Hemoccult and HemoQuant tests",
abstract = "Objectives. - To define the validity of fecal blood as a marker for colorectal neoplasia in the screening setting and to compare yields by Hemoccult and HemoQuant fecal occult blood screening tests. Design. - A multicenter masked comparison of fecal blood test results against structural colorectal evaluations and longitudinal follow-up, serving as criterion standards, in nonreferred subjects at risk for colorectal neoplasia. Setting. - Communities, primary care centers, referral centers. Participants. - Two groups: (1) 1217 patients aged at least 18 years undergoing routine structural surveillance evaluations following curative resection of a colorectal tumor and (2) 12 312 relatives of colorectal cancer patients aged at least 50 years. Interventions. - Blinded Hemoccult II and HemoQuant testing on three mailedin stool samples per subject. Main Outcome Measure. - Sensitivity of fecal blood tests for colorectal neoplasia. Results. - In the postresection group, surveillance evaluations revealed 46 malignant colorectal neoplasms and 402 polyps. At matched specificity, sensitivity of either test for cancer was 26{\%} (95{\%} confidence interval, 13{\%} to 39{\%}). Hemoccult was positive in 21{\%} of intraluminal recurrences, 33{\%} of all new primary tumors, and 29{\%} of Dukes A or B cancers; HemoQuant was elevated in 24{\%}, 28{\%}, and 29{\%}, respectively. Sensitivity for polyps 1.0 cm or larger was 13{\%} by Hemoccult and 11{\%} by HemoQuant. In the group of relatives, estimated sensitivity for cancer at 1 to 3 years of follow-up was 25{\%} to 33{\%} by Hemoccult, not significantly different from the 29{\%} to 43{\%} by HemoQuant. Conclusions. - Based on our observations in the screening setting, fecal blood appears to be a poor marker for colorectal neoplasia. Most cancers and the vast majority of polyps will be missed. Hemoccult and HemoQuant are similarly insensitive.",
author = "Ahlquist, {David A.} and Wieand, {Harry S.} and Moertel, {Charles G.} and McGill, {Douglas B.} and Loprinzi, {Charles Lawrence} and O'Connell, {Michael J.} and Mailliard, {James A.} and Gerstner, {James B.} and Kishan Pandya and Ellefson, {Ralph D.}",
year = "1993",
month = "3",
day = "10",
language = "English (US)",
volume = "269",
pages = "1262--1267",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Accuracy of fecal occult blood screening for colorectal neoplasia

T2 - A prospective study using Hemoccult and HemoQuant tests

AU - Ahlquist, David A.

AU - Wieand, Harry S.

AU - Moertel, Charles G.

AU - McGill, Douglas B.

AU - Loprinzi, Charles Lawrence

AU - O'Connell, Michael J.

AU - Mailliard, James A.

AU - Gerstner, James B.

AU - Pandya, Kishan

AU - Ellefson, Ralph D.

PY - 1993/3/10

Y1 - 1993/3/10

N2 - Objectives. - To define the validity of fecal blood as a marker for colorectal neoplasia in the screening setting and to compare yields by Hemoccult and HemoQuant fecal occult blood screening tests. Design. - A multicenter masked comparison of fecal blood test results against structural colorectal evaluations and longitudinal follow-up, serving as criterion standards, in nonreferred subjects at risk for colorectal neoplasia. Setting. - Communities, primary care centers, referral centers. Participants. - Two groups: (1) 1217 patients aged at least 18 years undergoing routine structural surveillance evaluations following curative resection of a colorectal tumor and (2) 12 312 relatives of colorectal cancer patients aged at least 50 years. Interventions. - Blinded Hemoccult II and HemoQuant testing on three mailedin stool samples per subject. Main Outcome Measure. - Sensitivity of fecal blood tests for colorectal neoplasia. Results. - In the postresection group, surveillance evaluations revealed 46 malignant colorectal neoplasms and 402 polyps. At matched specificity, sensitivity of either test for cancer was 26% (95% confidence interval, 13% to 39%). Hemoccult was positive in 21% of intraluminal recurrences, 33% of all new primary tumors, and 29% of Dukes A or B cancers; HemoQuant was elevated in 24%, 28%, and 29%, respectively. Sensitivity for polyps 1.0 cm or larger was 13% by Hemoccult and 11% by HemoQuant. In the group of relatives, estimated sensitivity for cancer at 1 to 3 years of follow-up was 25% to 33% by Hemoccult, not significantly different from the 29% to 43% by HemoQuant. Conclusions. - Based on our observations in the screening setting, fecal blood appears to be a poor marker for colorectal neoplasia. Most cancers and the vast majority of polyps will be missed. Hemoccult and HemoQuant are similarly insensitive.

AB - Objectives. - To define the validity of fecal blood as a marker for colorectal neoplasia in the screening setting and to compare yields by Hemoccult and HemoQuant fecal occult blood screening tests. Design. - A multicenter masked comparison of fecal blood test results against structural colorectal evaluations and longitudinal follow-up, serving as criterion standards, in nonreferred subjects at risk for colorectal neoplasia. Setting. - Communities, primary care centers, referral centers. Participants. - Two groups: (1) 1217 patients aged at least 18 years undergoing routine structural surveillance evaluations following curative resection of a colorectal tumor and (2) 12 312 relatives of colorectal cancer patients aged at least 50 years. Interventions. - Blinded Hemoccult II and HemoQuant testing on three mailedin stool samples per subject. Main Outcome Measure. - Sensitivity of fecal blood tests for colorectal neoplasia. Results. - In the postresection group, surveillance evaluations revealed 46 malignant colorectal neoplasms and 402 polyps. At matched specificity, sensitivity of either test for cancer was 26% (95% confidence interval, 13% to 39%). Hemoccult was positive in 21% of intraluminal recurrences, 33% of all new primary tumors, and 29% of Dukes A or B cancers; HemoQuant was elevated in 24%, 28%, and 29%, respectively. Sensitivity for polyps 1.0 cm or larger was 13% by Hemoccult and 11% by HemoQuant. In the group of relatives, estimated sensitivity for cancer at 1 to 3 years of follow-up was 25% to 33% by Hemoccult, not significantly different from the 29% to 43% by HemoQuant. Conclusions. - Based on our observations in the screening setting, fecal blood appears to be a poor marker for colorectal neoplasia. Most cancers and the vast majority of polyps will be missed. Hemoccult and HemoQuant are similarly insensitive.

UR - http://www.scopus.com/inward/record.url?scp=0027403221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027403221&partnerID=8YFLogxK

M3 - Article

C2 - 8437303

AN - SCOPUS:0027403221

VL - 269

SP - 1262

EP - 1267

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 10

ER -